Berit Markevärn

1.8k total citations
30 papers, 796 citations indexed

About

Berit Markevärn is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Berit Markevärn has authored 30 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 26 papers in Genetics and 10 papers in Rheumatology. Recurrent topics in Berit Markevärn's work include Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (10 papers). Berit Markevärn is often cited by papers focused on Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (10 papers). Berit Markevärn collaborates with scholars based in Sweden, Norway and Finland. Berit Markevärn's co-authors include Leif Stenke, Johan Richter, Magnus Björkholm, Ulla Olsson‐Strömberg, Martin Höglund, Anders Wåhlin, Marie Nilsson, Irina Golovleva, Arta Dreimane and Jan Samuelsson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical and Biophysical Research Communications.

In The Last Decade

Berit Markevärn

30 papers receiving 784 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Berit Markevärn Sweden	16	671	558	204	199	154	30	796
Milena Fava Italy	8	764 1.1×	352 0.6×	203 1.0×	389 2.0×	92 0.6×	10	949
Kátia Bórgia Barbosa Pagnano Brazil	13	384 0.6×	290 0.5×	133 0.7×	163 0.8×	118 0.8×	90	569
Jerry Radich United States	11	518 0.8×	248 0.4×	111 0.5×	89 0.4×	76 0.5×	29	602
Jenny Shan United States	13	1.2k 1.7×	923 1.7×	608 3.0×	135 0.7×	121 0.8×	26	1.3k
Patricia Martin‐Regueira United States	9	332 0.5×	206 0.4×	99 0.5×	109 0.5×	123 0.8×	21	464
Luigiana Luciano Italy	14	430 0.6×	294 0.5×	154 0.8×	116 0.6×	80 0.5×	32	622
Hagop M. Kantarjian United States	11	437 0.7×	256 0.5×	78 0.4×	81 0.4×	157 1.0×	17	650
Н Д Хорошко Russia	8	767 1.1×	651 1.2×	511 2.5×	76 0.4×	126 0.8×	13	883
Marie‐Pierre Noël France	10	712 1.1×	612 1.1×	314 1.5×	50 0.3×	163 1.1×	15	786
M Shtalrid Israel	12	309 0.5×	213 0.4×	81 0.4×	68 0.3×	67 0.4×	28	461

Countries citing papers authored by Berit Markevärn

Since Specialization

Citations

This map shows the geographic impact of Berit Markevärn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berit Markevärn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berit Markevärn more than expected).

Fields of papers citing papers by Berit Markevärn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berit Markevärn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berit Markevärn. The network helps show where Berit Markevärn may publish in the future.

Co-authorship network of co-authors of Berit Markevärn

This figure shows the co-authorship network connecting the top 25 collaborators of Berit Markevärn. A scholar is included among the top collaborators of Berit Markevärn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berit Markevärn. Berit Markevärn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Söderlund, Stina, Johan Richter, Susanne Saußele, et al.. (2024). Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Leukemia. 38(4). 781–787. 6 indexed citations

Ilander, Mette, Satu Mustjoki, Johan Richter, et al.. (2023). Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology. 102(6). 1395–1408. 5 indexed citations

Richter, Johan, Anna Lübking, Stina Söderlund, et al.. (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia. 35(8). 2416–2418. 16 indexed citations

Sandin, Fredrik, Torsten Dahlén, Anna Lübking, et al.. (2021). Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry. British Journal of Haematology. 193(5). 915–921. 10 indexed citations

Söderlund, Stina, Jesper Stentoft, Johan Richter, et al.. (2021). Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. European Journal Of Haematology. 107(6). 617–623. 5 indexed citations

Lübking, Anna, Arta Dreimane, Fredrik Sandin, et al.. (2019). Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplantation. 54(11). 1764–1774. 25 indexed citations

Kreutzman, Anna, Bhagwan Yadav, Tim H. Brümmendorf, et al.. (2019). Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunology. 8(9). e1638210–e1638210. 21 indexed citations

Rajala, Hanna, Perttu Koskenvesa, Tim H. Brümmendorf, et al.. (2017). Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143(8). 1543–1554. 19 indexed citations

Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30(9). 1853–1860. 49 indexed citations

10.

Höglund, Martin, Leif Stenke, Solveig Wållberg‐Jonsson, et al.. (2016). Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia. 30(7). 1562–1567. 17 indexed citations

11.

Christiansson, Lisa, Stina Söderlund, Sara M. Mangsbo, et al.. (2015). The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. Molecular Cancer Therapeutics. 14(5). 1181–1191. 57 indexed citations

12.

Björkholm, Magnus, Åsa Rangert Derolf, Malin Hultcrantz, et al.. (2011). Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology. 29(17). 2410–2415. 174 indexed citations

13.

Wåhlin, Anders, Rolf Billström, Ove Björ, et al.. (2009). Results of risk‐adapted therapy in acute myeloid leukaemia. A long‐term population‐based follow‐up study. European Journal Of Haematology. 83(2). 99–107. 34 indexed citations

14.

Palmblad, Jan, Magnus Björkholm, Jack Kutti, et al.. (2008). TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. International Journal of Medical Sciences. 5(2). 87–91. 6 indexed citations

15.

Gupta, Manu, et al.. (2007). Expression of BCR–ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. Biochemical and Biophysical Research Communications. 366(3). 848–851. 4 indexed citations

16.

Samuelsson, Jan, Hans Carl Hasselbalch, Øystein Bruserud, et al.. (2004). A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.. Blood. 104(11). 1518–1518. 3 indexed citations

17.

Höglund, Martin, Mats Brune, Bengt Sallerfors, et al.. (2003). More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML. Bone Marrow Transplantation. 32(12). 1119–1124. 2 indexed citations

18.

Wåhlin, Anders, Berit Markevärn, Irina Golovleva, & Marie Nilsson. (2002). Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. European Journal Of Haematology. 68(1). 54–63. 19 indexed citations

19.

Merup, Mats, Jack Kutti, Nils Mauritzson, et al.. (2002). Negligible Clinical Effects of Thalidomide in Patients with Myelofibrosis with Myeloid Metaplasia. Medical Oncology. 19(2). 79–86. 32 indexed citations

20.

Wåhlin, Anders, Berit Markevärn, Irina Golovleva, & Marie Nilsson. (2001). Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. British Journal of Haematology. 115(1). 25–33. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact